12:00 AM
 | 
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taxotere docetaxel: Phase III data; marketed to treat locally advanced or metastatic breast cancer after failure of prior chemotherapy

In a 373-patient U.S. Phase III trial, the one-year survival rate of patients treated with docetaxel was 32 percent compared to 19 percent...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >